esketamine | CARLAT PUBLISHING

Research Update

Esketamine vs Quetiapine in Treatment-Resistant Depression

November 1, 2024

Ivy Song, MD. Dr. Song has no financial relationships with companies related to this material.

Esketamine outperforms quetiapine in TRD remission rates, but the clinical significance of this difference remains uncertain.

Top 10 Findings: Lithium, Lumateperone, and Lavender

October 21, 2024

Chris Aiken, MD and Kellie Newsome, PMHNP

New studies change how we think about lithium and weight gain, and updates on lumateperone, lavender, and esketamine in depression.

Ketamine Assisted Therapy Part III

July 8, 2024

Chris Aiken, MD, Kellie Newsome, PMHNP, and Kyle T. Greenway, MD, MSc

Kyle Greenway developed the Montreal Model to pair ketamine with psychotherapy. In this 3-part series, he shows us how to do it.

Ketamine Assisted Therapy Part II

July 1, 2024

Kellie Newsome, PMHNP, Chris Aiken, MD, and Kyle T. Greenway, MD, MSc

Kyle Greenway developed the Montreal Model to pair ketamine with psychotherapy. In this 3-part series, he shows us how to do it.

Ketamine Assisted Therapy Part I

June 24, 2024

Chris Aiken, MD, Kellie Newsome, PMHNP, and Kyle T. Greenway, MD, MSc

Kyle Greenway developed the Montreal Model to pair ketamine with psychotherapy. In this 3-part series, he shows us how to do it.

Expert Q&A

Ketamine Use and Misuse

April 1, 2024

Keith A. Trujillo, PhD

Keith A. Trujillo, PhD.

Emeritus Professor of Psychology, California State University, San Marcos, CA.

Dr. Trujillo has no financial relationships with companies related to this material.

Ketamine and esketamine represent some of the most powerful rapid-acting agents in our armamentarium of treatments for depression. However, ketamine is also an addictive substance, and there is emerging evidence that the widespread use of ketamine may be causing more patient harms than we were previously aware of. Here, Dr. Trujillo discusses how to use ketamine safely in clinical practice.

Clinical Update

Six Recent Disappointments in Psychiatric Research

February 1, 2024

Chris Aiken, MD

Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Assistant Professor, NYU Langone Department of Psychiatry. Practicing psychiatrist, Winston-Salem, NC.

Dr. Aiken has no financial relationships with companies related to this material.

Find out where standard therapies like cariprazine and esketamine have failed in recent trials, along with novel medications like minocycline, zuranolone, pimavanserin, and NAC.

CARLAT WEBINAR

Ketamine and the Evolving Psychopharmacologic Pipeline for Depression

December 8, 2023

Robert C. Meisner, MD

0.50 CME Credits. Robert Meisner, MD, explores the latest developments in psychiatric treatment with ketamine and esketamine, including their differences and emerging insights for clinicians.

Screen Shot 2023-11-12 at 1.13.49 PM.png

Ketamine: Six New Findings Part 2

November 13, 2023

Chris Aiken, MD and Kellie Newsome, PMHNP

New research brings clarity to the big ketamine questions. How does it compare to ECT and antipsychotics? How much of it is placebo? Which is more effective – ketamine or esketamine? How do you sustain the benefits? Does it work better with psychotherapy?

Screen Shot 2023-11-05 at 6.56.55 PM.png

Ketamine: Six New Findings Part 1

November 6, 2023

Chris Aiken, MD and Kellie Newsome, PMHNP

New research brings clarity to the big ketamine questions. How does it compare to ECT and antipsychotics? How much of it is placebo? Which is more effective – ketamine or esketamine? How do you sustain the benefits? Does it work better with psychotherapy?